Bigul

DR.REDDY'S LABORATORIES LTD. - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
14-10-2024
Bigul

Dr Reddy's F&O contract adjustments

The stock split will lead to necessary adjustments in the futures and options (F&O) contracts on this stock on the record date
12-10-2024
Bigul

DR.REDDY'S LABORATORIES LTD. - 500124 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Issue of Letter of confirmation in lieu of share certificate(s) reported lost/ misplaced
11-10-2024
Bigul

DR.REDDY'S LABORATORIES LTD. - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
10-10-2024
Bigul

DR.REDDY'S LABORATORIES LTD. - 500124 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018
07-10-2024
Bigul

DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Acquisition

Incorporation of step down wholly-owned subsidiary
05-10-2024
Bigul

DR.REDDY'S LABORATORIES LTD. - 500124 - Fixation Of Record Date For Sub-Division / Split Of The Equity Shares Of The Company Pursuant To Regulation 42 Of The SEBI (LODR) Regulations, 2015

Fixation of Record date for Sub-division / split of the Equity shares of the Company pursuant to Regulation 42 of the SEBI (LODR) Regulations, 2015
04-10-2024
Bigul

Dr Reddy's ties up with Gilead to manufacture, commercialise HIV drug

Dr Reddy's Laboratories on Wednesday said it has tied up with Gilead Sciences for the manufacture and commercialisation of the HIV drug Lenacapavir in India and 120 other countries. The company has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences Ireland UC for the drug, the Hyderabad-based drug maker said in a statement. Lenacapavir is a US Food and Drug Administration (USFDA) approved drug indicated for the treatment of human immunodeficiency virus a type 1 (HIV-1) infection in heavily treatment-experienced adults with multi-drug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. Additionally, Lenacapavir is currently under investigation for the prevention of HIV (PrEP) which is yet to be approved globally. Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the US and Europe markets in the year 2022. As per the agreement, Dr Reddy's w
02-10-2024
Next Page
Close

Let's Open Free Demat Account